Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Regulatory press release

Scandinavian ChemoTech's Animal Care division signs exclusive distribution agreement for the Australian and New Zealand market

Scandinavian ChemoTech
Download the release

Vetiqure AB has today entered a strategic collaboration with Gamma Gurus Pty Ltd by signing an exclusive distribution agreement for the Australian and New Zealand veterinary market.

After over a 12-month extensive search and evaluation of over 20 potential distributors, we are very happy to announce that our top choice, Gamma Gurus, has now become a part of the Vetiqure family. This distribution agreement will generate one order of at least one vetIQure™ system, which will be activated after local ethics committee approval, before the end of January 2023.

Parallel to this agreement, ChemoTech is also in ongoing discussions with Gamma Gurus to expand into the human market with IQwave™.

"I am excited that we now can introduce our TSE technology to the Australian and New Zealand veterinary market, through a very established and knowledgeable distributor. This is truly an important market for Animal Care. It's of course also a huge possibility for Human Care as Australia and New Zealand have the highest rates of skin cancer. We see our technology being able to make a difference as a new therapy in the fight against this form of cancer, amongst others." - says Mohan Frick, CEO of Scandinavian ChemoTech AB

About Gamma Gurus Pty Ltd
Gamma Gurus brings over 100 years of experience in diagnostic imaging, radiation therapy and radioactive material management together in one place. Their goal is to provide unsurpassed solutions and service to their customers with a professional and hassle-free attitude. Their extensive network ensures that they will be able to source the best products from around the world to meet the needs of the local healthcare community. Their decades of local knowledge guarantee that suppliers and customers alike have the support to navigate the complex regulatory, logistics and technical nuances of the local markets.

This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 18-10-2022 15:30 CET.

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.